Quarterly report · Q3
3151.TEDINET S100SUKH
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥448.9bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥581.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥444.4bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥5.7bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥6.5bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥7.6bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.1bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.1bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.1bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥328.3bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥297.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥336.1bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥225.6bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥197.2bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥102.7bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥100.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥102.4bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥31.1bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥19.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥99.12 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.66 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.69 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.59 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.22 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.1% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-12-31 | ¥4.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-12-31 | ¥2.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-12-31 | −¥162m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥10.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥10.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | ¥61m |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥431.3bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥423.2bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥14.3bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥14.3bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥9m |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥259m |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥8.5bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥8.5bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥0 |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥288m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥454.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥446.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥8.0bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥458.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥448.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥5.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥4.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | −¥236m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥9.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥9.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥126m |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥427.4bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥419.4bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥77m |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥283m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥449.4bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥441.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥454.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥444.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 377
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes | Prior1YTDDuration | 1622000000 | JPY |
| Income taxes | CurrentYTDDuration | 2490000000 | JPY |
| Profit loss | Prior1YTDDuration | 2510000000 | JPY |
| Profit loss | CurrentYTDDuration | 5134000000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | 77000000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | 80000000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 2433000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 5054000000 | JPY |
| Profit loss | Prior1YTDDuration | 2510000000 | JPY |
| Profit loss | CurrentYTDDuration | 5134000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | 2416000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 1327000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | -267000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | -273000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | Prior1YTDDuration | 81000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | CurrentYTDDuration | 337000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 2230000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 1391000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 4740000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 6526000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 4663000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 6445000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 77000000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 80000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 419449000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember | 13769000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 8164000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 441384000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3000000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 444384000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 444384000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 7976000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember | 6000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 7983000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1896000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9880000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -9880000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 427426000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember | 13776000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 8164000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 449367000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4896000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 454264000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -9880000000 | JPY |
| Net sales | Prior1YTDDuration | 444384000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 2810000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember | 77000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |